915
Views
7
CrossRef citations to date
0
Altmetric
Letter to the Editor

Vaccine coverage in PLWH: disparities and potential impact of vaccine hesitancy

, , &

References

  • Tsachouridou O, Georgiou A, Naoum S, Vasdeki D, Papagianni M, Kotoreni G, et al. Factors associated with poor adherence to vaccination against hepatitis viruses, streptococcus pneumoniae and seasonal influenza in HIV-infected adults. Hum Vaccines Immunother. 2018 Aug;15.
  • Frésard A, Gagneux-Brunon A, Lucht F, Botelho-Nevers E, Launay O. Immunization of HIV-infected adult patients - French recommendations. Hum Vaccines Immunother. 2016 Jul;13:1–13.
  • Larson HJ, de Figueiredo A, Xiahong Z, Schulz WS, Verger P, Johnston IG, Cook AR, Jones NS. The State of vaccine confidence 2016: global insights through a 67-Country Survey. EBioMedicine. 2016 Oct;12:295–301. doi:10.1016/j.ebiom.2016.08.042.
  • Thomas CM, Loewen A, Coffin C, Campbell NRC. Improving rates of pneumococcal vaccination on discharge from a tertiary center medical teaching unit: a prospective intervention. BMC Public Health. 2005 Oct;14(5):110. doi:10.1186/1471-2458-5-110.
  • Gallone MS, Martino C, Quarto M, Tafuri S. Active offer of vaccinations during hospitalization improves coverage among splenectomized patients: an Italian experience. Am J Infect Control. 2017 Aug 1;45(8):e87–9. doi:10.1016/j.ajic.2017.02.039.
  • Crum-Cianflone NF, Wallace MR. Vaccination in HIV-Infected Adults. AIDS Patient Care STDs. 2014 Jul 16;28(8):397–410. doi:10.1089/apc.2014.0121.
  • Valour F, Cotte L, Voirin N, Godinot M, Ader F, Ferry T, Vanhems P, Chidiac C. Vaccination coverage against hepatitis A and B viruses, Streptococcus pneumoniae, seasonal flu, and A(H1N1)2009 pandemic influenza in HIV-infected patients. Vaccine. 2014 Jul 31;32(35):4558–4564. doi:10.1016/j.vaccine.2014.06.015.
  • Günthard HF, Wong JK, Spina CA, Ignacio C, Kwok S, Christopherson C, Hwang J, Haubrich R, Havlir D, Richman DD. Effect of influenza vaccination on viral replication and immune response in persons infected with human immunodeficiency virus receiving potent antiretroviral therapy. J Infect Dis. 2000 Feb;181(2):522–531. doi:10.1086/315260.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.